Anodyne Nanotech Raises $12.6 Million Series A to Advance Weekly GLP-1 Patch for Obesity and Expand Transdermal Drug Delivery Platform
Anodyne Nanotech Inc., a clinical-stage biotechnology company focused on transforming chronic disease treatment through transdermal drug delivery, has announced the successful close of a $12.6 million Series A financing round. The new capital is expected to accelerate the company’s lead obesity program, ANN-101, while also expanding its broader transdermal delivery platform designed for a range of complex therapeutics, including peptides, monoclonal antibodies, and nucleic acid-based medicines.
The financing round was led by Velocity Partners VC and co-led by Evercurious VC, with significant participation from Relativity Healthcare Partners. The raise marks a pivotal step for Anodyne as it pushes toward clinical development of its lead candidate and positions its technology platform as a potential alternative to injectable therapies in chronic disease management.
Funding to Support Clinical Advancement of ANN-101
According to the company, the proceeds from the Series A round will primarily be used to move ANN-101, Anodyne’s once-weekly GLP-1 patch for obesity, into a Phase I clinical trial. Beyond the lead program, the financing will also support scale-up of manufacturing operations, expansion of the company’s transdermal platform capabilities, and the advancement of strategic partnership efforts that could broaden the reach of its delivery technology.
The company is betting that transdermal delivery could help address some of the key challenges that continue to shape the obesity treatment market. GLP-1-based therapies have rapidly become one of the most important segments in modern medicine, driving strong demand due to their effectiveness in supporting weight loss and metabolic control. However, many of the leading products in the category rely on injection-based administration and often require cold-chain storage, factors that can create inconvenience for patients and complicate long-term treatment adherence.
Anodyne’s lead candidate, ANN-101, is being developed as a once-weekly patch that aims to deliver therapeutic levels of a GLP-1 medicine through the skin, potentially eliminating the need for injections. If successful, such an approach could offer patients a more convenient treatment option and potentially improve adherence in a chronic disease setting where long-term compliance is essential for sustained benefit.
Company Positions ANN-101 as a Potential Alternative to Injectable GLP-1 Therapies
Jake Lombardo, Chief Executive Officer of Anodyne Nanotech, described the financing as an important inflection point for the company and a validation of its vision for transdermal chronic care delivery. He said the company’s lead obesity program targets a major unmet need in a disease area that has moved to the center of healthcare and pharmaceutical innovation.
Lombardo noted that Anodyne has demonstrated the ability to deliver multi-milligram weekly doses of a GLP-1 therapy through a patch and achieve exposure levels consistent with what obesity treatment requires. He emphasized that the platform is designed to do so without the need for injection-based administration or cold storage, two factors that have become central differentiators in the increasingly competitive obesity market.
The company also highlighted what it sees as one of the platform’s most important technical advantages: the ability to deliver large therapeutic doses through a patch. That capability, Anodyne believes, could unlock opportunities for co-formulation, allowing multiple active ingredients to be combined and delivered through a single transdermal system rather than through multiple separate treatments.
This feature is especially relevant as obesity drug development evolves beyond single-agent approaches and toward combination therapies designed to improve efficacy, durability of weight loss, and preservation of metabolic health.
Combination Patch Program Aims to Address Lean-Mass Loss in Obesity Treatment
In addition to ANN-101, Anodyne is also advancing a second obesity-focused candidate that combines apelin and GLP-1 in a single transdermal patch. The company says this program is intended to address one of the most pressing challenges associated with GLP-1-driven weight loss: loss of lean muscle mass.
While GLP-1 therapies have shown powerful weight reduction benefits, they have also raised concern among clinicians and researchers about the extent to which patients may lose not only fat mass but also lean tissue during treatment. Preserving muscle mass has become an increasingly important topic in obesity care, especially as pharmaceutical developers look to improve the overall quality of weight loss and support healthier long-term outcomes.
Anodyne believes its combination patch strategy could help counter that issue by pairing a GLP-1 agent with apelin, a peptide associated with metabolic and muscle-related effects. The goal is to create a more balanced obesity treatment approach that supports weight reduction while helping to mitigate the lean-mass loss often seen with current therapies.
Lombardo suggested that the company sees this follow-on candidate as a natural extension of the platform’s capabilities and a reflection of how transdermal delivery could support more sophisticated therapeutic combinations over time.
Broader Platform Ambitions Beyond Obesity
Although obesity is currently the company’s most visible focus, Anodyne is positioning its technology as a much broader transdermal delivery engine for complex biologic and advanced therapeutic medicines. The company said the Series A proceeds will also be used to accelerate development of its delivery platform for peptides, monoclonal antibodies, and nucleic acid therapeutics.
That ambition is notable because many of these classes of medicines have traditionally been difficult to formulate for convenient non-injectable delivery. Injectable administration remains the standard for a wide range of biologics and advanced therapies, but it can be burdensome for patients—particularly those living with chronic conditions that require repeated dosing over long periods of time.
By simplifying administration and reducing dependence on needles, Anodyne hopes to make therapies easier to use while also enabling more flexible pharmacokinetic control. The company says its platform is designed not only to avoid injections, but also to offer tunable pharmacokinetics, a feature that could allow drug release and absorption to be optimized based on the needs of a specific therapeutic application.
If validated clinically, that combination of convenience and dosing control could make transdermal delivery attractive in multiple disease areas beyond obesity.
Board Strengthened with Addition of Veteran Pharma Executive Vikram Lamba
Alongside the financing announcement, Anodyne also revealed that Vikram Lamba has joined the company’s Board of Directors, adding a seasoned pharmaceutical executive with extensive experience in corporate development, strategic transactions, and biotech leadership.
Lamba brings more than three decades of experience spanning both global pharmaceutical companies and emerging biotech firms. He previously served as Chief Executive Officer of Zosano Pharma, where he helped oversee a $425 million strategic partnership with Eli Lilly focused on microneedle technology and also led the company through its initial public offering. Earlier in his career, he held senior roles in mergers and acquisitions and corporate development at Bayer AG, including serving as Director of M&A.
His appointment comes at a time when Anodyne is preparing to transition its lead asset into human studies while also building out strategic partnerships and evaluating future commercialization pathways. The addition of a board member with deep transaction and product development experience could prove valuable as the company navigates both financing and partnering discussions.
Investors See Potential in Needle-Free Delivery for Complex Medicines
For Anodyne’s investors, the company’s appeal appears to lie not just in the obesity opportunity, but in the broader promise of a delivery platform that could reshape how complex medicines are administered.
George Papastergiou, Partner at Velocity Partners VC, said Anodyne is building what he described as a delivery layer for the next generation of complex medicines. He pointed to the continued reliance on injections for biologic drugs as a major barrier for patients, particularly in chronic conditions where convenience and adherence play an important role in treatment success.
Papastergiou said Anodyne’s needle-free transdermal platform is designed to provide injectable-grade performance while also enabling more patient-friendly administration and potentially reducing treatment friction. He added that the platform’s tunable pharmacokinetics could help improve therapeutic performance and side-effect management, while the company’s early GLP-1 results and multiple commercialization paths make it a compelling player in the obesity market.
Positioned at the Intersection of Obesity Innovation and Drug Delivery
Anodyne’s financing comes at a time when the obesity market is attracting unprecedented attention from pharmaceutical companies, investors, and healthcare systems worldwide. The success of GLP-1-based therapies has created a race not only to develop new molecules, but also to improve how those therapies are delivered, tolerated, and combined with other agents.
In that context, Anodyne is positioning itself at the intersection of two powerful trends: the rapid expansion of obesity therapeutics and the search for more convenient, patient-centric delivery systems for biologics and other advanced medicines. With fresh capital in hand, the company now faces the challenge of translating platform promise into clinical proof, beginning with the planned Phase I evaluation of ANN-101.
If the program succeeds, it could help establish a new category of obesity treatment—one in which weekly metabolic therapies are delivered not by pen injectors or refrigerated vials, but by a patch designed to simplify treatment and improve the patient experience. More broadly, it could validate Anodyne’s ambition to bring transdermal delivery into therapeutic areas that have long remained dependent on needles.
For now, the Series A financing provides the company with the resources to take that next step, advancing its obesity pipeline, expanding its delivery technology, and building the strategic foundation for what it hopes will become a new model for chronic care.
About Anodyne Nanotech
Anodyne Nanotech is a biotechnology company, developing next-generation transdermal therapeutics. The company’s solid-state microneedle technology is designed to deliver multi-milligram doses of large molecules (peptides, antibodies, and nucleic acid therapeutics) through a convenient, room-temperature-stable patch, while maintaining injection-level efficacy. Anodyne’s lead program, ANN-101, is a once-weekly GLP-1 patch for obesity. The company is headquartered in Boston, Massachusetts.
